A Phase I/II Study of Intratumoral Injection of Ipilimumab in Combination With Local Radiation in Melanoma, Non-Hodkgkin Lymphoma and Colorectal Carcinoma
Latest Information Update: 31 Jan 2024
At a glance
- Drugs Ipilimumab (Primary)
- Indications Anaplastic large cell lymphoma; Burkitt's lymphoma; Colon cancer; Cutaneous B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Diffuse lymphoma; Follicular lymphoma; Hairy cell leukaemia; Malignant melanoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Rectal cancer; Sezary syndrome; T-cell leukaemia; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 04 Jan 2024 The Phase of this study has been amended to Phase 1 as phase 2 of this study was not conducted.
- 12 Jan 2017 Status changed from suspended to discontinued.
- 20 Nov 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.